CARsgen Therapeutics
4022 Stirrup Creek Drive
Durham
NC
United States
61 articles about CARsgen Therapeutics
-
CARsgen Releases the First Clinical Batch of CAR T Cells from its RTP GMP Manufacturing Facility in North Carolina
9/2/2022
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), announces that the company’s Current Good Manufacturing Practice (CGMP) manufacturing facility located at the Research Triangle Park (RTP) in North Carolina, the United States of America (“The RTP GMP Manufacturing Facility”) has started GMP production of autologous CAR T-cell products and successfully released the first GMP batch for the clinical trials.
-
CARsgen 2022 Interim Results: Innovative CAR T-cell Technologies and Robust Pipeline
8/24/2022
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, has announced the 2022 Interim Results.
-
CEL-SCI Corporation, Jazz Pharmaceuticals, CARsgen and Ascentage Pharma presented clinical trial data at the American Society of Clinical Oncology 2022 Annual Meeting.
-
CARsgen Therapeutics Presents Updated Data for CT041 Claudin18.2 CAR T-cells in Solid Tumors at ASCO 2022
6/6/2022
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
Achilles dosed the first patient in a Phase I/IIa advanced NSCLC trial, Logic Bio's pediatric methylmalonic acidemia study is back up and running and another look at Roche's TIGIT flop.
-
Nature Medicine Publishes Results from an Investigator-Initiated Trial of CARsgen's CT041 Claudin18.2 CAR T Cells in Gastrointestinal Cancers
5/10/2022
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), announces that the phase I trial interim results of an investigator-initiated trial of CT041 have been published in Nature Medicine (https://www.nature.com/articles/s41591-022-01800-8), which is one of the top international medical journals in the Nature Portfolio (2-year Impact Factor of 53.44).
-
CARsgen Therapeutics Opens New U.S. cGMP Facility for CAR T Production
2/21/2022
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies announced that its current Good Manufacturing Practices (cGMP) manufacturing facility located at the Research Triangle Park (RTP) in North Carolina, the United States of America ("The RTP Manufacturing Facility") has successfully passed the official inspections by local government.
-
CARsgen Therapeutics to Celebrate the Completion of Its cGMP Commercial Manufacturing Facility with Design and Construction Partner, CRB
2/21/2022
CARsgen Therapeutics, a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced today the grand opening of the newly completed 37,000-ft2 clinical and early-stage commercial manufacturing facility.
-
CARsgen Presents Updated Research Results on BCMA CAR T-cell Product (CT053) at 2021 ASH Annual Meeting
12/13/2021
CARsgen Therapeutics Holdings Limited today announces that at the 2021 American Society of Hematology ("ASH") Annual Meeting, the Company presented two posters with study results for CT053, an autologous CAR T-cell product candidate against B-Cell Maturation Antigen (BCMA).
-
CARsgen Receives CTA Authorization from Health Canada for CLDN18.2-targeted CAR T-cell Product CT041
11/22/2021
CARsgen Therapeutics Holdings Limited today announced that the Company has received a No Objection Letter from Health Canada in response to the Clinical Trial Application (CTA) of CT041.
-
Appealing Data of CARsgen Therapeutics' CAR-T (CT041) in Advanced Gastric Cancer Presented at ESMO
9/20/2021
On September 19, 2021, CARsgen Therapeutics disclosed the latest progress of the investigator-initiated trial of Claudin18.2 CAR-T for the treatment of digestive system tumors.
-
CARsgen is building a new $157 million CAR-T manufacturing facility in Durham, that is expected to create approximately 200 new jobs.
-
CARsgen Therapeutics Receives Orphan Medicinal Product Designation from the European Medicines Agency for CT041 CLDN18.2 CAR T Cells for the Treatment of Gastric Cancers
3/1/2021
CARsgen Therapeutics Holdings Limited, a clinical-stage biopharmaceutical company, announced that the European Commission has granted orphan designation for CT041, CARsgen's first-in-class Claudin 18.2 targeted CAR-T product candidate for the treatment of gastric cancer.
-
CARsgen Therapeutics Presents Updated Multiple Myeloma Cell Therapy Data at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition
12/6/2020
CARsgen Therapeutics, a clinical-stage biopharmaceutical company, announced updated safety and efficacy results from its ongoing global clinical studies of CT053, an investigational chimeric antigen receptor T-cell therapy for patients with relapsed and/or refractory multiple myeloma.
-
CARsgen Therapeutics to Present Multiple Myeloma Cell Therapy Data at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition in December
11/20/2020
CARsgen Therapeutics announced that data from its global multiple myeloma program will be presented, including two oral presentations and one poster session, at the 62nd American Society of Hematology Annual Meeting and Exposition, taking place virtually December 5-8, 2020.
-
Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.
-
CARsgen Therapeutics Closes a USD 186 Million Series C Equity Financing to Accelerate Global Clinical Trials of its Cell Therapy Product Candidates
11/2/2020
CARsgen Therapeutics Holdings Limited, a leading biotechnology company focused on innovation and development of chimeric antigen receptor T-cell therapeutics, announced the completion of a USD 186 million Series C Equity Financing.
-
CARsgen Therapeutics Granted Orphan Drug Designation by the US FDA for CT041 CLDN18.2 CAR-T Cells for the Treatment of Gastric and Gastroesophageal Junction Cancers
10/5/2020
CARsgen Therapeutics Co., Ltd., a clinical-stage biopharmaceutical company, announced that the United States Food and Drug Administration has granted orphan drug designation to one of CARsgen's first-in-class drug candidates, CT041, for the treatment of gastric and gastroesophageal junction adenocarcinoma.
-
CARsgen Therapeutics Receives IND Clearance from the NMPA for CT041 CLDN18.2-CAR-T Cells
8/20/2020
CARsgen Therapeutics Co., Ltd. announced that the National Medical Products Administration has cleared its Investigational New Drug application for the first-in-class drug candidate CT041, autologous chimeric antigen receptor T cells for the treatment of claudin18.2-positive solid tumors.
-
CARsgen Announces the Publication of a Novel CAR-T Technology that Improves the Efficacy of CAR-T cells Against Solid Tumors without Requiring Preconditioned Lymphodepletion
8/17/2020
CARsgen Therapeutics, a leader in developing novel CAR-T cell therapies against solid tumors, announced its publication of the 7×21 CAR-T technology in CLINICAL CANCER RESEARCH.